“Drug discovery, distilled.”
A knowledge platform photographed at close range: no lab coat, no beaker, just a search bar that 200 of the world's drug companies point at the same impossible question - what did everybody publish this week, and which molecule actually matters?
There is a certain kind of business that sounds boring until you notice who pays for it.
Here is a fact about drug discovery that is both obvious and, somehow, unsolved. Every week, thousands of papers, patents, and conference disclosures land in the world's chemistry literature. Somewhere in that pile is the one molecule that changes your program - or a competitor's. And no human being can read all of it. This is not a technology problem, exactly. The papers are right there. It is a time problem, which is worse, because you cannot fix a time problem by trying harder.
Drug Hunter's answer is almost aggressively simple: hire scientists who used to do the work, have them read everything, and have them write down what matters. Then make it searchable. That's the company. You can describe the whole thing in three words - “drug discovery, distilled” - which is either a red flag or a very good sign, and in this case it is a very good sign, because the customer list is the kind you cannot fake.
More than 200 R&D institutions subscribe, including Eli Lilly, Biogen, Merck KGaA, Deerfield Management, the National Institutes of Health, and - this is the detail that amuses me - Isomorphic Labs, the AI-first drug company. Think about that. A company whose entire premise is that machines can predict molecular structure still pays humans to tell it what happened in the literature last week. The lesson is not that AI is overrated. The lesson is that curation and computation are different jobs.
What you actually get is a set of tools that sound mundane and are quietly load-bearing. There's Molecule Search, a database of drug structures pulled from papers and patents and cleaned up by people who know what they're looking at. There's Patent Search, which is competitive intelligence dressed as a search box. There are courses, Flash Talks, and a recurring feature called Molecules of the Month that chemists apparently look forward to, the way other people look forward to a magazine.
Most startups begin with a business plan and go looking for a problem. Drug Hunter began the other way around. Dennis X. Hu had a PhD from Stanford, a stint as a Senior Scientist in Discovery Chemistry at Genentech, and a specific, personal frustration: keeping up with new drugs was miserable, and the existing tools were built for librarians, not chemists. So in 2018 he started writing things up. The writing was useful. Useful things attract readers. Readers, eventually, become customers. Revenue came last, which is the correct order and almost nobody does it.
The result is a company that reads like an editorial operation with a subscription business bolted on - which, if you squint, is exactly what a good research tool should be. The moat here is not code. It's judgment: knowing which of the week's thousand molecules is the one to flag. That is hard to copy and gets more valuable as the pile of literature grows.
“Drug Hunter is like having your smartest colleagues read every journal for you, then just tell you the key insights.”
Wendy Young - former SVP, GenentechEverything Drug Hunter builds points at the same job: get the signal, skip the noise.
A searchable database of drug structures and molecular insights, distilled from literature, patents, and early disclosures by industry scientists.
Search and analyze patent disclosures relevant to your program - competitive intelligence for medicinal chemists.
Structured education on drug discovery: structure-based design, modalities, and the druggable interactome.
Short-form curated talks highlighting key developments in medicinal chemistry - the good bits, without the two-hour seminar.
iOS and Android app that surfaces new drug disclosures and curated insights to scientists as they happen.
“It's the kind of resource I wish had existed earlier in my career.”
Mark Murcko - Founding CSO, Relay Therapeutics“Drug Hunter distills the core knowledge of our field and makes it accessible.”
Chris Helal - Biogen“Few resources combine scientific rigor with day-to-day utility the way Drug Hunter does.”
Ken Brameld - Alumis“Drug Hunter complements our approach, providing trusted, high-quality drug discovery insights.”
Rebecca Paul - Isomorphic LabsWhen Eli Lilly and the NIH both point at the same search box, that tells you something.
PhD, Stanford. Dual BA/MS, Northwestern. Before Drug Hunter, Dennis was a Senior Scientist in Discovery Chemistry at Genentech and held roles from Scientist I to Senior Scientist at RAPT Therapeutics, working on small-molecule drug discovery and cancer immunology. He didn't leave the bench to escape science - he left to fix the part of it that wasted everyone's time. Drug Hunter is what a chemist builds when he's tired of missing the paper that mattered.
Dennis X. Hu starts writing up new drugs and the science behind them, out of frustration with how hard they were to keep up with.
The write-ups grow into a platform - molecule search, patent search, courses - adopted across pharma and biotech R&D.
Fresh capital to expand scientific coverage, enrich the structure database, sharpen search and analytics, and build out the mobile app.
Recurring curated features and course content - the druggable interactome - keep chemists coming back.
Drug Hunter began in 2018 out of one scientist's frustration with keeping up with new drugs.
Its founder holds a PhD from Stanford and was a Senior Scientist in Discovery Chemistry at Genentech.
“Molecules of the Month” is a recurring feature chemists actually look forward to reading.
Even AI-first drug company Isomorphic Labs is a subscriber - human curation still matters.
The entire promise fits in three words: “drug discovery, distilled.”
Watch talks, demos and Flash Talks on the Drug Hunter YouTube channel - product walkthroughs and interviews with drug discovery scientists.